Anzeige
Mehr »
Login
Freitag, 01.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Neuer Gold Rekord bei knapp 2.800 USD und Übernahme-Zirkus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
259 Leser
Artikel bewerten:
(1)

Neon Bloom Inc.: Neon Bloom, Inc. Returns to Current Information Status with OTC Markets Group

Company retains Global Business Strategies Inc. and appoints Fred Luke as Secretary and Board member

COLUMBIA, MD / ACCESSWIRE / July 24, 2023 / Neon Bloom, Inc. (OTC PINK:NBCO), announces that it has completed updating its required disclosure reports and has returned to Current Information status with the OTC Markets Group, resulting in the removal of the "Yield" designation and the return to full compliance with the OTC Markets Group Alternative Reporting Standards.

Commenting on the removal of the "Yield" designation and the Company's return to Current Information status, Michael Elzufon, Chairman of Neon Bloom, Inc., stated, "We are pleased to see the Yield designation removed. We've been working closely with Mr. Fred Luke and Global Business Strategies to complete the updating and posting of all the Company's Disclosure Statements together with current Financial Statements on OTCMarkets.com for the Two (2) years ended December 31, 2021 and 2022, and the recent fiscal quarter ended March 31, 2023.

"I believe this will not only instill confidence with our current shareholders", said Mr. Elzufon, "but should attract other investors and sources of working capital. And, in the process of updating the Company's Disclosure Statements and financials, we've also completed a minor restructuring which will allow us to continue forward as a holding company with investments in healthcare, technology, financial services, and emerging markets."

"As part of our restructuring", said Mr. Elzufon, "we appointed Fred Luke to serve as our Secretary and as a member of our Board of Directors. Mr. Luke has a storied career of success: over the past 40 years he has served as an executive, director, officer, investor and as an advisor to numerous public companies, and his experience, combined with his robust day to day performance, will bode well for our company and its shareholders."

The Company's historical focus has been in the health & wellness space through the Company's subsidiary, Bazelet Health Systems Inc., which has developed PECSA, a patent pending cannabis plant-based ingredient for the food, drug and cosmetic industries.

About Neon Bloom:

Neon Bloom, Inc. (OTC: NBCO) is a holding company for investments in healthcare, financial services and businesses in synergistic industries. Beginning in 2023 NBCO began to expand its leadership team and its investments in new acquisitions; in 2021 it acquired Bazelet Health Systems, Inc. ("Bazelet") acquired in an all-stock transaction, and currently operates Bazelet as a wholly owned subsidiary. The Company intends to make additional acquisitions in the near future utilizing shares of its common stock, non-convertible promissory performance-based notes, and cash as is available.

About Bazelet Health Systems, Inc:

Bazelet, is the licensed US plant patent, trademark, and manufacturer of PAN2020, the world's first patented cannabis plant (US Plant Patent number US PP32,725 P2). PAN2020 is a new and distinct variety of cannabis sativa (L.) plant and contains 0.00% tetrahydrocannabinol (THC), making it the first and only federally legal cannabis plant. With Pan2020, Bazelet developed the proprietary ingredient PECSA (Plant-based Endo Cannabinoid System Activator), used in the manufacturing and commercial supply of food, drug, and cosmetic products that comply with the Food, Drug and Cosmetic Act. There are no health care claims being made by the Company or Bazelet about the PECSA products; these products are not intended to treat, diagnose, mitigate, prevent, or cure diseases, nor do they have any therapeutic effect as to any specific medically diagnosed conditions.

Forward Looking Statements:

This press includes "forward-looking statements", that involve risks and uncertainties. All statements other than statements of historical facts, included in this press release that address activities, events, or developments that we expect or anticipate will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strength, goals, expansion and growth of our business and operations, plans, references to future success, reference to intentions as to future matters, and other such matters are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. These statements are based upon certain assumptions and analyses made by us considering our experience and our perception of historical trends, current conditions and expected future developments as well as other factors that we believe are appropriate in the circumstances. However, whether actual results and developments will conform to our expectations and predictions is subject to several risks, uncertainties, and other factors, many of which are beyond our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, we do not assume responsibility for the accuracy and completeness of such forward-looking statements. We are under no duty to update any of the forward-looking statements after the date of this release to confirm such statements to actual results.

Contact Details:

news@neonbloominc.com
Shareholder Relations: 1- 888- 411-5350

SOURCE: Neon Bloom Inc.
via PRISM Mediawire, LLC

View source version on accesswire.com:
https://www.accesswire.com/769932/Neon-Bloom-Inc-OTC-NBCO-Returns-to-Current-Information-Status-with-OTC-Markets-Group

© 2023 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.